Search Within

Martin Henner Voss

Formats
  1. Meeting Abstract (150)
  2. Journal Article (122)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (288)
  2. Genitourinary Oncology Service (288)
  3. Solid Tumor Oncology Division (288)
  4. Human Oncology and Pathogenesis Program (104)
  5. Weinberg Fellows (104)
  6. Surgery (103)

More Groups

People
  1. Robert Motzer (176)
  2. Abraham Hakimi (95)
  3. Darren Feldman (80)
  4. Chung-Han Lee (75)
  5. Maria Carlo (65)
  6. Ritesh Kotecha (63)

More People

Years
  1. 2025 (6)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (116)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (120)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (18)
  6. Biomed Central Ltd (15)

More Publishers

Results (288)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma
    Meeting Abstract

    Kotecha, R.; Lee, C. H.; McHugh, D. J.; Dadoun, C.; Knezevic, A.; Carlo, M. I.; Feld, E.; Shapnik, N.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Part 1 results from NOVA-II, a randomized, double-blind, vehicle-controlled phase II study evaluating the safety and efficacy of OQL011 on VEGFR inhibitor associated hand-foot skin reaction in cancer patients
    Meeting Abstract

    Lacouture, M. E.; Patel, A. B.; Le Boeuf, N. R.; Marathe, O. S.; Leventhal, J.; Choi, J. N.; Lam, E. T.; Kaffenberger, B. S.; Voss, M. H.; Webb, M. L.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Choueiri, T. K.; Plimack, E. R.; Powles, T.; Voss, M. H.; Gurney, H.; Silverman, R. K.; Perini, R. F.; Rodriguez-Lopez, K.; Rini, B. I.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: An open-label phase I trial
    Journal Article

    Meric-Bernsta, F.; Tannir, N. M.; Iliopoulos, O.; Lee, R. J.; Telli, M. L.; Fan, A. C.; DeMichele, A.; Haas, N. B.; Patel, M. R.; Harding, J. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN Renal 101 trial
    Journal Article

    Bilen, M. A.; Rini, B. I.; Voss, M. H.; Larkin, J.; Haanen, J. B. A. G.; Albiges, L.; Pagliaro, L. C.; Voog, E. G.; Lam, E. T.; Kislov, N.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
    Journal Article

    Nguyen, B.; Fong, C.; Luthra, A.; Smith, S. A.; DiNatale, R. G.; Nandakumar, S.; Walch, H.; Chatila, W. K.; Madupuri, R.; Kundra, R.; more...
    Cell (2022)

    Fulltext@MSK | Save
  • Novel standards and emerging therapies for systemically treatment-naìˆve clear cell renal cell carcinoma - A rapidly changing landscape
    Review

    Kotecha, R. R.; Voss, M. H.
    Journal of Cancer Metastasis and Treatment (2021)

    Fulltext@MSK | Save
  • Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma
    Meeting Abstract

    Choueiri, T.; Plimack, E.; Powles, T.; Voss, M.; Gurney, H.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Rini, B.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • In silico modeling of combination systemic therapy for advanced renal cell carcinoma
    Journal Article

    Kotecha, R. R.; Hsu, D. J.; Lee, C. H.; Patil, S.; Voss, M. H.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Germline variants identified in patients with early-onset renal cell carcinoma referred for germline genetic testing
    Journal Article

    Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Reisz, P. A.; Lenis, A. T.; Mehta, N. N.; Khurram, A.; Joseph, V.; Mandelker, D.; more...
    European Urology Oncology (2021)

    Fulltext@MSK | Save